Aisha Elsharkawy1, Maissa El-Raziky2, Wafaa El-Akel2, Kadry El-Saeed3, Rasha Eletreby2, Mohamed Hassany4, Manal Hamdy El-Sayed5, Khaled Kabil6, Sohier A Ismail4, Magdy El-Serafy2, Ashraf Omar Abdelaziz2, Mohamed Kamal Shaker7, Ayman Yosry2, Wahid Doss2, Yehia El-Shazly3, Gamal Esmat2, Imam Waked8. 1. Endemic Medicine and Hepatogastroentrology Department, Faculty of Medicine, Cairo University, Cairo, Egypt. Electronic address: a_m_sharkawy@yahoo.com. 2. Endemic Medicine and Hepatogastroentrology Department, Faculty of Medicine, Cairo University, Cairo, Egypt. 3. Internal Medicine Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt. 4. Tropical Medicine Department, National Hepatology & Tropical Medicine Research Institute, Cairo, Egypt. 5. Pediatrics Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt. 6. New Pediatric Children Hospital, Cairo University, Cairo, Egypt. 7. Tropical Medicine Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt. 8. Department of Hepatology, National Liver Institute, Menoufiya University, Menoufiya, Egypt.
Abstract
BACKGROUND AND AIMS: The introduction of direct-acting antivirals for hepatitis C virus (HCV) in Egypt led to massive treatment uptake, with Egypt's national HCV treatment program becoming the largest in the world. The aim of this paper is to present the Egyptian experience in planning and prioritizing mass treatment for patients with HCV, highlighting the difficulties and limitations of the program, as a guide for other countries of similarly limited resources. METHODS: Baseline data of 337,042 patients, treated between October 2014 to March 2016 in specialized viral hepatitis treatment centers, were grouped into three equal time intervals of six months each. Patients were treated with different combinations of direct-acting antivirals, with or without ribavirin and pegylated interferon. Baseline data, percentage of patients with known outcome, and sustained virological response at week 12 (SVR12) were analyzed for the three cohorts. The outcomes of 94,258 patients treated in the subsequent two months are also included. RESULTS: For cohort-1, treatment was prioritized for patients with advanced fibrosis (F3-F4 fibrosis, liver stiffness ≥9.5 kPa, or Fibrosis-4 ≥3.25). Starting cohort-2, all stages of fibrosis were included (F0-F4). The prioritization strategy in the initial phase caused delays in enrollment and massive backlogs. Cohort-1 patients were significantly older, and more had advanced fibrosis compared to subsequent cohorts. The percentage of patients with known SVR12 results were low initially, and increased with each cohort, as several methods to capture patient results were adopted. Sofosbuvir-ribavirin therapy for 24 weeks had the lowest SVR12 rate (82.7%); while other therapies were associated with SVR12 rates between 94% and 98%. CONCLUSION: Prioritization based on fibrosis stage was not effective and enrollment increased greatly only after including all stages of fibrosis. The availability of generic drugs reduced costs, and helped massively increase uptake of the program. Post-treatment follow-up was initially very low, and although this has increased, further improvement is still needed. LAY SUMMARY: We are presenting the largest national program for HCV treatment in the world. We clearly demonstrate that hepatitis C can be cured efficiently in large scale real-life programs. This is a clear statement that global HCV eradication is foreseeable, providing a model for other countries with limited resources and prevalent HCV. Moreover, the availability of generic products has influenced the success of this program.
BACKGROUND AND AIMS: The introduction of direct-acting antivirals for hepatitis C virus (HCV) in Egypt led to massive treatment uptake, with Egypt's national HCV treatment program becoming the largest in the world. The aim of this paper is to present the Egyptian experience in planning and prioritizing mass treatment for patients with HCV, highlighting the difficulties and limitations of the program, as a guide for other countries of similarly limited resources. METHODS: Baseline data of 337,042 patients, treated between October 2014 to March 2016 in specialized viral hepatitis treatment centers, were grouped into three equal time intervals of six months each. Patients were treated with different combinations of direct-acting antivirals, with or without ribavirin and pegylated interferon. Baseline data, percentage of patients with known outcome, and sustained virological response at week 12 (SVR12) were analyzed for the three cohorts. The outcomes of 94,258 patients treated in the subsequent two months are also included. RESULTS: For cohort-1, treatment was prioritized for patients with advanced fibrosis (F3-F4 fibrosis, liver stiffness ≥9.5 kPa, or Fibrosis-4 ≥3.25). Starting cohort-2, all stages of fibrosis were included (F0-F4). The prioritization strategy in the initial phase caused delays in enrollment and massive backlogs. Cohort-1 patients were significantly older, and more had advanced fibrosis compared to subsequent cohorts. The percentage of patients with known SVR12 results were low initially, and increased with each cohort, as several methods to capture patient results were adopted. Sofosbuvir-ribavirin therapy for 24 weeks had the lowest SVR12 rate (82.7%); while other therapies were associated with SVR12 rates between 94% and 98%. CONCLUSION: Prioritization based on fibrosis stage was not effective and enrollment increased greatly only after including all stages of fibrosis. The availability of generic drugs reduced costs, and helped massively increase uptake of the program. Post-treatment follow-up was initially very low, and although this has increased, further improvement is still needed. LAY SUMMARY: We are presenting the largest national program for HCV treatment in the world. We clearly demonstrate that hepatitis C can be cured efficiently in large scale real-life programs. This is a clear statement that global HCV eradication is foreseeable, providing a model for other countries with limited resources and prevalent HCV. Moreover, the availability of generic products has influenced the success of this program.
Authors: Margaret Hellard; Sophia E Schroeder; Alisa Pedrana; Joseph Doyle; Campbell Aitken Journal: Cold Spring Harb Perspect Med Date: 2020-04-01 Impact factor: 6.915
Authors: Nick Scott; Rachel Sacks-Davis; Amanda J Wade; Mark Stoove; Alisa Pedrana; Joseph S Doyle; Alexander J Thompson; David P Wilson; Margaret E Hellard Journal: Med J Aust Date: 2020-03-13 Impact factor: 7.738
Authors: Caitlin H Douglass; Alisa Pedrana; Jeffrey V Lazarus; Ellen F M 't Hoen; Radi Hammad; Ricardo Baptista Leite; Andrew Hill; Margaret Hellard Journal: BMC Med Date: 2018-10-09 Impact factor: 8.775